BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

FDA Speeds Review of Bayer AG (BAY.F), Algeta's Prostate Cancer Drug


8/23/2011 8:07:55 AM

Germany's Bayer AG (BAYN.XE) and Norwegian partner Algeta ASA (ALSETA.OS) Tuesday said that U.S. drug regulators designated their experimental therapy Alpharadin for fast track approval, reinforcing views the prostate cancer medicine might have the potential for sales of over $1 billion. The U.S. Food and Drug Administration's decision to fast track Alpharadin follows recent clinical trial data showing it improved overall survival in patients with castration-resistant prostate cancer and symptomatic bone metastases. The trial was stopped early due to the impressive overall survival results.

Read at Market Watch
Read at Reuters
Read at Wall Street Journal
Read at Street Insider

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->